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INTRODUCTION
In the last two decades, genetic studies of inherited forms of human
cardiomyopathy have offered important insights into the fundamental
biology of myocardial hypertrophy and heart failure. Many of the
causal genes for inherited hypertrophic cardiomyopathy (HCM)
encode for proteins involved in the proper function of the cardiac
sarcomere. However, substantial pleiotropy is seen for many
cardiomyopathy genes. Even within families harboring the same
mutation there is significant variation in the extent of hypertrophy,
the risk of arrhythmias or the progression to heart failure (Alcalai et
al., 2007; Arad et al., 2002). Furthermore, different mutations in a
single gene can lead to either HCM or dilated cardiomyopathy (DCM)
(Seidman and Seidman, 2001). The major modifiers regulating this
phenotypic diversity have not been defined.
Evidence is emerging of significant overlap between the pathways
regulating cell division and those driving cardiac hypertrophy
(Ahuja et al., 2007). Nuclear division and polyploidy are observed
in the later stages of human heart failure and resolve with
ventricular unloading, but cellular dynamics earlier in hypertrophy
have not yet been explored (Rivello et al., 2001). The limited capacity
for cell division in adult mammalian cardiomyocytes leads to the
chronic activation of cell division pathways; these same pathways
are thought to drive the changes in cardiomyocyte differentiation
seen in the hypertrophic process. The effects of manipulating cell
division pathways on myocardial growth are diverse and might
involve epigenetic mechanisms with complex inheritance patterns
(Wagner et al., 2008).
In an effort to define the earliest elements of the response to
hypertrophic stimuli, we have generated a zebrafish model of a
human cardiac troponin T (TNNT2) mutation known to cause
HCM. This model not only facilitates the study of the initial
developmental effects of a primary cause of hypertrophic
cardiomyopathy, but also allows the systematic study of genetic and
environmental modifiers before the effects of chronic myocardial
remodeling supervene.
In order to precisely recapitulate a human TNNT2 disease
mutation in the zebrafish, we designed morpholino antisense
oligonucleotides (oligos) that target the intron 13 splice donor site
in the zebrafish cardiac troponin T (tnnt2) mRNA. The resultant
sequence is orthologous to an established human TNNT2 splice
mutant and its expression is importantly under the control of the
native zebrafish tnnt2 promoter. Morphant hearts exhibited
disrupted sarcomere formation and showed induction of a
pathological transcriptional response during the earliest stages of
cardiogenesis. In addition, in these embryonic hearts, we confirmed
that Tnnt2 mutations lead to significant myocardial hyperplasia.
We also demonstrate that this Tnnt2 mutation perturbs normal
cardiomyocyte Ca2+ handling, suggesting that the arrhythmic risk
in the context of sarcomeric protein mutations does not simply
reflect the consequences of cellular disarray and scarring. Lastly,
once the genetic stimulus is eliminated, sarcomerogenesis
normalizes. Taken together, these data highlight the distinctive
initial responses of the embryonic heart to a primary hypertrophic
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SUMMARY
To assess the effects during cardiac development of mutations that cause human cardiomyopathy, we modeled a sarcomeric gene mutation in the
embryonic zebrafish. We designed morpholino antisense oligonucleotides targeting the exon 13 splice donor site in the zebrafish cardiac troponin
T (tnnt2) gene, in order to precisely recapitulate a human TNNT2 mutation that causes hypertrophic cardiomyopathy (HCM). HCM is a disease
characterized by myocardial hypertrophy, myocyte and myofibrillar disarray, as well as an increased risk of sudden death. Similar to humans with
HCM, the morphant zebrafish embryos displayed sarcomere disarray and there was a robust induction of myocardial hypertrophic pathways. Microarray
analysis uncovered a number of shared transcriptional responses between this zebrafish model and a well-characterized mouse model of HCM.
However, in contrast to adult hearts, these embryonic hearts developed cardiomyocyte hyperplasia in response to this genetic perturbation. The
re-creation of a human disease-causing TNNT2 splice variant demonstrates that sarcomeric mutations can alter cardiomyocyte biology at the earliest
stages of heart development with distinct effects from those observed in adult hearts despite shared transcriptional responses.
Human cardiomyopathy mutations induce myocyte
hyperplasia and activate hypertrophic pathways during
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stimulus, despite evidence of substantial sharing of sarcomeric
biology and transcriptional pathways with adult myocardium.
RESULTS
The zebrafish Tnnt2 splice variant genocopies the human disease-
causing TNNT2 splice variant
In order to precisely recapitulate an autosomal dominant
hypertrophic cardiomyopathy mutation, we chose to model a
mutation in the splice donor site of exon 15 in human TNNT2
(Thierfelder et al., 1994). The mutant TNNT2 mRNA splice
products either exclude exon 15 or use a cryptic splice site that
changes the reading frame and leads to a premature stop codon
(Fig. 1A). We used a morpholino (TNNT2sp MO) to target the
splice donor site in zebrafish tnnt2 exon 13, which is the ortholog
of human TNNT2 exon 15 (detailed sequence data for zebrafish
tnnt2 in supplementary material Fig. S1). The resulting morphant
splice product excludes zebrafish tnnt2 exon 13 (Fig. 1B), causing
a disruption in the C-terminus of the zebrafish Tnnt2 protein at
the identical position to that mutated in humans (Fig. 1C). This
morpholino allows the creation of a dominant mutation in Tnnt2
while retaining the full control of the native zebrafish tnnt2
promoter. In an effort to model the nature of the human disease
as precisely as possible, the TNNT2sp MO was dosed so that the
wild-type tnnt2 transcript was reduced by approximately 50% (Fig.
1B).
Morphant ventricles exhibit restrictive physiology and diminished
contractility
There was no evidence of non-cardiac or off-target morpholino
effects in the TNNT2sp morphants and the embryos developed at
a normal rate (Fig. 2A). Gross morphological examination of the
morphants showed a smaller ventricle, dilated atria and pericardial
edema compared with controls (Fig. 2B). Measurement of the
ventricular internal chamber dimensions at end diastole [end-
diastolic diameter (EDD; largest ventricular diameter)] and end
systole [end-systolic diameter (ESD; smallest ventricular diameter)]
confirmed substantial reductions in EDD in morphants compared
with control embryos (control EDD 55±1.1 m; TNNT2sp MO
EDD 31±1.6 m; P<0.005, n5). ESD was also significantly
decreased but to a lesser extent (control ESD 25±1.4 m; TNNT2sp
MO ESD 21±0.68 m; P<0.04, n5) (Fig. 2C). TNNT2sp morphants
also exhibited significant reductions in ventricular fractional
shortening (FS) (control FS 0.54; TNNT2sp MO FS 0.33; P<0.005,
n5) (Fig. 2D). Videos of control and TNNT2sp morphant hearts
are included in supplementary material Movies 1 (control) and 2
(TNNT2sp morphant) (both at 72 hpf).
Defective tnnt2 splicing causes sarcomeric disarray in the
embryonic heart
Mutant sarcomeric proteins frequently perturb sarcomere
assembly. Therefore, we performed electron microscopy of control
and TNNT2sp morphants to explore the ultrastructure of the
embryonic heart. There was marked sarcomeric disarray in the
TNNT2sp morphants, which was not present in control embryos
at 96 hpf (Fig. 3A). The altered mRNA splicing induced by injection
of the TNNT2sp MO is temporary and the morpholino effect is
gradually diluted through cell division during development. We
tested 8- and 21-day-old embryos that had recovered from the
initial morpholino injection to determine whether disruption of
early sarcomere structure persists despite the elimination of the
primary genetic stimulus. Although, sarcomere disarray was
apparent in 8-dpf embryos, by 21 dpf there were no ultrastructural
differences observed between control- and TNNT2sp-MO-injected
embryos (Fig. 3A).
Tnnt2 mutation induces embryonic myocardial hyperplasia
Sarcomeric mutations are a stimulus for cardiomyocyte
hypertrophy, which, in adult mammalian cardiomyocytes, seems
to occur in isolation with no evidence of cardiomyocyte division
(Ahuja et al., 2007). The effects of typical hypertrophic stimuli on
embryonic cardiomyocytes remain unclear. We quantified the
total number of cardiomyocytes in control and TNNT2sp
morphant embryos using a cmlc2::DsRed-nuc transgenic zebrafish
reporter line [red fluorescent protein (DsRed-nuc) expressed under
the control of the cardiac myosin light chain-2 (cmlc-2) promoter]
that fluorescently labels the nuclei of differentiated cardiomyocytes
(Mably et al., 2003). These embryos were injected with TNNT2sp
or control morpholino and cardiomyocyte nuclei were counted at
48 and 96 hpf. The nuclei numbers were similar at 48 hpf (control
197±22, n4; TNNT2sp MO 204±14, n5; PNS) but, at 96 hpf,
the TNNT2sp morphant hearts had approximately 26% more
DsRed-positive nuclei than control hearts (control 247±7, n4;
TNNT2sp MO 311±14, n3; P<0.03) (Fig. 3B). There was no
evidence of bi-nucleated cardiomyocytes; therefore, total nuclear
count correlates with total cardiomyocyte count. Ventricular
cardiomyocyte cell size was measured to determine whether
morphant cardiomyocytes underwent cellular hypertrophy
secondary to the presence of mutant tnnt2 splice product.
Morphant ventricular cardiomyocytes did not undergo hypertrophy
but were actually slightly smaller than control cardiomyocytes
(control 109±6 m2, n15; TNNT2sp MO 94±4 m2, n11; P<0.04)
(Fig. 3C).
Tnnt2 mutations perturb embryonic cardiomyocyte Ca2+ handling
Abnormal cardiomyocyte Ca2+ handling is thought to be a
stimulus for arrhythmias in patients with sarcomeric gene
mutations (Baudenbacher et al., 2008; Knollmann et al., 2003).
We performed high-resolution Ca2+ imaging in order to determine
the effects of sarcomeric mutation on cardiomyocyte Ca2+
handling during early heart development. The most striking
difference between TNNT2sp morphant and control embryos was
the shortening of the Ca2+ transient duration (CTD50) in the
TNNT2sp morphants. This shortening was observed in both
atrium and ventricle (Fig. 4C) (supplementary material Table S1).
Zebrafish null for Tnnt2 (TNNT2atg) were also analyzed to
determine whether the reduction in CTD50 was a distinctive
feature of the mutant RNA resulting from the TNNT2sp MO or
was a result of loss or absence of wild-type Tnnt2 protein.
TNNT2atg hearts, which never contract, exhibited a significant
reduction of CTD50 in the atrioventricular canal, but did not
develop significant reductions of CTD50 in the atrium or
ventricle. In contrast to changes seen in CTD50, diastolic Ca2+
levels and Ca2+ transient amplitudes in TNNT2sp morphants were
not significantly different to control hearts across multiple
locations (Fig. 4A,B; supplementary material Fig. S2 and Table
S1). However, TNNT2atg hearts showed significant changes
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compared with controls in these two parameters in multiple
different locations (Fig. 4A,B; supplementary material Table S1).
These data suggest that the splice mutant Tnnt2 protein results
in an early ‘gain-of-function’ effect on embryonic cardiomyocyte
Ca2+ handling, quite distinct from the effects of null tnnt2 alleles
(TNNT2atg).
Transcriptional responses to mutant Tnnt2
The typical gene expression signature induced in the setting of
sarcomeric dysfunction in adult animals is referred to as
reactivation of the ‘fetal gene program’. This group of genes includes
the cardiac natriuretic peptides NPPA and NPPB, as well as isoform
switching of myosin heavy chain genes. We were interested to
determine whether these transcriptional pathways could be
pathologically induced during cardiac development. We performed
a microarray analysis of gene expression in TNNT2sp- and control-
MO-injected morphants. Interestingly, we saw a significant
induction of the zebrafish ortholog of NPPA (average 2.9-fold
increase; Q value<0.03). A direct comparison of myosin heavy chain
isoform changes from zebrafish to mammals cannot be made
because, to date, no zebrafish ortholog of myh7 (beta-myosin heavy
chain) has been identified. Two cardiac myosin heavy chain genes
have been characterized in the zebrafish, myh6 (also known as atrial
myosin heavy chain) and vmhc (ventricular myosin heavy chain).
Fig. 1. A human TNNT2 splice mutation is
copied in zebrafish by using a splice
targeting morpholino. (A)A human TNNT2
intron 15 mutation that causes two different
mutant splice products of TNNT2.
(B)Morpholino targeting of zebrafish tnnt2
exon 13 causes mis-splicing of tnnt2 mRNA,
resulting in a smaller gene product (smaller
band on agarose gel). (C)Comparison of
human and zebrafish TNNT2 wild-type and
mutant protein sequences (box around exon
15 human/exon 13 zebrafish).
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Zebrafish Myh6 and Vmhc proteins are more closely related to
mouse Myh6 (-myosin heavy chain) than mouse Myh7 (NCBI,
Blast Protein Alignment). Notably, zebrafish myh6 gene expression
was increased 1.73-fold in the TNNT2sp morphant embryos,
whereas vmhc expression was not significantly changed (Fig. 5A,
black bar; Q value0.11). The other sarcomeric genes evaluated on
the microarray are presented for comparison. Of note, one probe
specifically bound to exon 13 of zebrafish tnnt2, allowing us to
independently assess the efficacy of our TNNT2sp MO. The
TNNT2sp morphants had a significant reduction in wild-type tnnt2
mRNA compared with embryos injected with a control morpholino
[Fig. 5A, white bar labeled ‘tnnt2 (exon 13)’; Q value0.006]. A
second tnnt2 probe that bound the 3 untranslated region of tnnt2
mRNA also showed reduced levels of expression in the TNNT2sp
morphants [Fig. 5A, white bar labeled ‘tnnt2 (3 UTR)’; Q
value0.06].
Given the significant reduction in CTD50 seen in our TNNT2sp
morphants, we evaluated the list of differentially expressed genes
to identify potential transcriptional differences that might explain
these effects. In the morphants, we found upregulation of several
genes that are known to regulate cardiomyocyte Ca2+ homeostasis
– the cardiac sodium/calcium exchanger (slc8a1a), calsequestrin
2 (casq2), sarcalumenin (srl) and calpastatin (cast) (Harris et al.,
2006; Kubalova et al., 2004; Yoshida et al., 2005) (Fig. 5B).
We next undertook formal analysis of the microarray datasets
for pathway enrichment in the morphant using FuncAssociate
(Berriz et al., 2003). The only genetic pathway that was significantly
perturbed in TNNT2sp morphants was a group of genes classified
under the gene ontology term ‘hormone activity’ (GO:0005179),
all of which were coordinately downregulated. The specific
genes  associated with this pathway included growth hormone
releasing hormone (ghrh), parathyroid hormone (pth1a),
proopiomelanocortin (pomca) and urotensin2a (uts2a) (Fig. 5C).
To confirm that the microarray accurately reflects gene
expression changes, we performed quantitative reverse-
transcriptase PCR (qPCR) on select upregulated (>twofold
increased) and downregulated (>50% decreased) genes identified
on the microarray. The microarray and qPCR results show similar
levels of up- or down-regulation (Fig. 5D).
Lastly, to explore the extent to which the embryonic zebrafish
TNNT2sp transcriptional responses parallel those in adult
mammalian HCM models, we compared our whole-embryo dataset
with an HCM gene expression dataset from mouse ventricular
tissue generated with Polony Multiplex Analysis of Gene Expression
Fig. 2. TNNT2sp morphants have reduced ventricular
dimensions and impaired ventricular function.
(A)Comparison of control-injected (top) and TNNT2sp
morphant (bottom) embryos at 96 hpf. (B)Representative
high-magnification image of control (left) and TNNT2sp
morphant (right) heart (A, atria; V, ventricle; atria not visible
in control). (C)Chamber dimensions in control (black bar)
and TNNT2sp morphants (gray bar). (D)FS in control (black
bar) and TNNT2sp morphants (gray bar). *P<0.05; n5 for all
measurements. All data expressed as mean + s.e.m.
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(P-MAGE) (Kim et al., 2007). The mouse ventricular tissue that
was analyzed was harvested from alphaMHC403 heterozygote
mice. These mice harbor a missense mutation in their alpha
myosin heavy chain gene (myh6) that causes a change from arginine
to glutamine at position 403 (Geisterfer-Lowrance et al., 1996). The
expression of 122 genes was significantly changed in both our tnnt2
morphant zebrafish dataset and the mouse alphaMHC403 HCM
P-MAGE dataset. Of these genes, 74 were regulated in a concordant
fashion and 48 were regulated in a discordant fashion (cumulative
binomial probability0.012) (Fig. 6). Induction of the natriuretic
peptide gene nppa and multiple genes encoding Ca2+ regulatory
proteins was seen in both datasets (casq2, cast and srl). In addition,
there was concordant downregulation of a number of genes
important to cardiovascular biology (abcc9, foxo1 and hey1).
DISCUSSION
Our embryonic zebrafish model of a human sarcomeric gene
mutation recapitulated many of the cellular and transcriptional
responses seen in adult organisms with these mutations. In the
context of a hypertrophic stimulus, even the initial embryonic
cardiomyocytes exhibited sarcomeric disarray, a hallmark of
sarcomeric gene mutations in humans and mammalian models.
These cellular phenomena were accompanied by a robust
transcriptional response closely paralleling the patterns of gene
expression observed in a murine model of HCM. In addition, there
was a significant perturbation of cardiomyocyte Ca2+ handling
evident during cardiogenesis in this zebrafish model. Despite these
similarities with adult HCM models, the embryonic zebrafish heart
did not display cardiomyocyte hypertrophy in response to this
sarcomeric mutation, but rather developed significant
cardiomyocyte hyperplasia.
The recapitulation of this human TNNT2 splicing abnormality
has dramatic effects on early cardiomyocyte sarcomerogenesis, and
these seem to be reversible in the embryonic heart. Interestingly,
the disruption in sarcomerogenesis persisted for a considerable
period (several days) after the abnormal tnnt2 splice product was
eliminated but, by 21 dpf, the sarcomere had fully remodeled and
normal sarcomerogenesis was evident. These observations suggest
that even the profound abnormalities of sarcomeric structure seen
in human cardiomyopathic cells might be reversible if the genetic
mutation can be ‘silenced’ through chemical or genetic means.
Nevertheless, the sarcomere recovery that we have observed in
morphant embryos might reflect distinctive characteristics of the
zebrafish embryonic heart, and post-natal mammalian sarcomeres
might not be so plastic. Indeed, recent data in a rabbit model of
HCM suggest that, although chemical modifiers might be able to
reverse the interstitial fibrosis and cardiomyocyte hypertrophy
associated with longstanding HCM, they do not modify myocyte
disarray (Lombardi et al., 2009).
Despite the phylogenetic distance between zebrafish and
mammals, there is substantial conservation of the gene expression
responses to sarcomeric gene mutations. One of the most highly
upregulated genes in the TNNT2sp morphant embryos is nppa.
This induction of the natriuretic peptide pathway is a consistent
feature of mammalian models of HCM and acquired hypertrophy.
There was robust correlation of gene expression in our morphant
with published cardiac gene expression analysis in an adult mouse
HCM model across multiple pathways. The transcriptional effects
seen in our zebrafish embryos were evident despite the potential
limitations of whole-embryo expression profiling. These data
highlight the fundamental nature of the hypertrophic
transcriptional program, which is activated virtually from the
onset of cardiac function in this zebrafish model of HCM.
One advantage of whole-embryo expression profiling is that
systemic responses to cardiac-restricted stimuli can be assessed.
Developing an understanding of how the whole organism responds
to altered cardiac function could provide useful insights into the
pathophysiology of hypertrophy and the factors determining
progression to the systemic syndrome of congestive heart failure.
Comprehensive pathway analyses of gene expression in our
Fig. 3. Disruption of sarcomere structure and induction of myocardial
hyperplasia in TNNT2sp morphants. (A)Representative electron
micrographs of 96 hpf (top), 8 dpf (middle) and 21 dpf (bottom) ventricular
cardiomyocytes. (B)Total cardiomyocytes at 48 hpf and 96 hpf.
(C)Cardiomyocyte area at 96 hpf. *P<0.05; n3-5 hearts per time point. All data
expressed as mean + s.e.m.
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embryonic zebrafish TNNT2sp model demonstrated
downregulation of a group of hormonal genes. Interestingly, these
same neuroendocrine genes have been shown to modify
cardiomyocyte survival (ghrh and pth1a) (Cha et al., 2009; Granata
et al., 2009), directly modulate the cardiomyocyte hypertrophic
response (uts2) (Tzanidis et al., 2003) or are transcriptionally
regulated by hypertrophic pathways (pomca) (Chalmers et al.,
2008).
Another aspect of the pleiotropy of HCM is the variable risk of
cardiac arrhythmias. In animal models of HCM, arrhythmias can
develop before significant fibrosis occurs, suggesting that primary
alterations in cardiomyocyte electrical properties, in addition to
Fig. 4. Distinct alterations in Ca2+ handling induced by altered TNNT2 splicing. Diastolic (A) and transient amplitude (B) Ca2+ measurements in specific heart
regions in controls, TNNT2sp morphants and TNNTatg (null) morphants. (C)CTD50 measured in atrium, atrioventricular canal (AVC), outer ventricular curvature
(OC), mid-ventricle (MV) and inner ventricular curvature (IC). Asterisk donates P<0.05 for comparison of TNNT2sp morphant with control sample, or TNNT2atg
morphant with control. All data expressed as mean ± s.e.m. 
Fig. 5. Altered tnnt2 splicing induces significant
changes in the expression of sarcomeric genes,
neurohormonal genes and markers of hypertrophy.
(A)Expression profiling identifies upregulation of myh6
(black bar) and confirms efficacy of TNNT2sp MO [white bar
labeled ‘tnnt2 (Exon 13)’. (B)Genes involved in
cardiomyocyte Ca2+ handling that are differentially
regulated in TNNT2sp morphants. (C)Pathway analysis
identifies significant downregulation of expression of
genes encoding specific hormones – ghrh, pth1a, pomca
and uts2a. (D)qPCR confirmation of select up- and
downregulated genes. All data expressed as mean + s.e.m.
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fibrotic scarring, underlie the arrhythmogenesis (Baudenbacher et
al., 2008; Wolf et al., 2005). Our TNNT2sp morphants had
significant shortening of CTD50 in both atrium and ventricle.
Interestingly, complete loss of Tnnt2 resulted in distinctive effects
on diastolic Ca2+ concentrations and on the amplitude of the Ca2+
transient. These differences suggest that competing effects on Ca2+
handling result from the deletion of different domains within Tnnt2,
and these non-overlapping roles might explain the disparate effects
of individual troponin mutations on Ca2+ sensitivity in vitro
(Szczesna et al., 2000). Among the potential mechanisms for the
reduced CTD50 observed in the TNNT2sp morphants are effects
on sarcomeric buffering of cytoplasmic Ca2+ or the upregulation
of a number of Ca2+ handling proteins – slc8a1a, casq2 and srl.
Increased expression of slc8a1a and the sarcoplasmic reticulum
(SR) genes casq2 and srl would facilitate extrusion of Ca2+ from
the cytoplasm to the extracellular space or SR, respectively (Harris
et al., 2006; Kubalova et al., 2004; Yoshida et al., 2005). The role of
cast is less clear, but it has been shown to bind and modulate the
activity of Cav1.2, the cardiac L-type calcium channel (Hao et al.,
2000). The precise mechanisms by which reduction in CTD50
might result in arrhythmogenesis are not known. However,
abnormalities in CTD50 are seen in animal models of
catecholaminergic polymorphic ventricular tachycardia (CPVT)
(Song et al., 2007).
Cellular hypertrophy is a fundamental response of the stressed
heart. Many of the pathways associated with cell division are known
to be activated in this hypertrophic response, leading to the
hypothesis that cardiomyocyte hypertrophy might be the result of
a fundamental block in karyokinesis and cytokinesis, by which the
adult cardiomyocyte is unable to disassemble sarcomeres, uncouple
from neighboring cells and divide (Ahuja et al., 2007). Nuclear
division and polyploidy are observed in the latest stages of human
heart failure and reverse with ventricular unloading, but cellular
dynamics earlier in the pathophysiological cascade have not yet
been explored (Rivello et al., 2001). In the zebrafish model that we
generated, we were able to explore the effects of disrupted
sarcomere gene function during cardiogenesis. We found that when
the embryonic heart is exposed to a hypertrophic stimulus, in
contrast to the response in the adult mammalian heart, a
hyperplastic response occurs. Whereas pressure or volume overload
seem to increase cardiomyocyte proliferation in the fetal
mammalian heart, the effects of such hypertrophic stimuli on the
relevant molecular pathways have not been identified (Saiki et al.,
1997; Sedmera et al., 2003). We were able to show that, despite the
hyperplastic nature of the embryonic response to a primary
hypertrophic stimulus, the classic hypertrophic transcriptional
stress response networks are activated in this zebrafish model.
Cross-species comparison of the distinctive molecular networks
Fig. 6. Conservation of gene expression between the
zebrafish and mouse models of sarcomeric protein
mutations. The zebrafish genes that were concordantly
upregulated (blue) or downregulated (brown) compared
with a mouse model of HCM are displayed in a heatmap. Top
– most upregulated gene; bottom – most downregulated
gene. Each column corresponds to a unique biological
replicate.
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regulating cardiomyocyte hypertrophy and hyperplasia could offer
insights into the factors determining these differential responses
to a single stimulus.
It is interesting to compare our findings with those in a murine
model with transgenic overexpression of a comparable truncated
TNNT2 protein under the control of the alphaMHC(myh6)
promoter (Tardiff et al., 1998). In both fish and mouse there was
evidence of reduced ventricular chamber dimensions and some
impairment of contractile function. In the transgenic mouse there
was evidence of reduced cell number, but in the fish we observed
increased cell number, despite the reduction in chamber
dimensions, with a parallel reduction in cell size. Importantly, this
particular transgenic mouse model did not exhibit evidence of
induction of the typical transcriptional markers of the hypertrophic
response, unlike other vertebrate cardiac troponin T models
(Tardiff et al., 1999). It remains to be seen whether these differences
between mouse and fish models result from the onset of mutant
allele expression in different time windows (the alphaMHC
promoter does not become active until late in cardiac development),
or from intrinsic differences between murine and zebrafish
cardiomyocytes.
Although zebrafish models of complete loss of TNNT2 or
truncation of the TNNT2 protein exist, we designed our approach
to precisely recapitulate a known human sarcomeric gene mutation
while maintaining comprehensive native regulation and wild-type
hemizygous gene dose. Zebrafish homozygous for a null tnnt2
mutation (silent heart), with severe truncation of Tnnt2 protein or
lack of translation, develop ultrastructural characteristics of HCM,
mainly sarcomeric disarray. However, these recessive zebrafish
tnnt2 mutants, as well as the cognate homozygous tnnt2-null
mouse, never exhibit myocardial contraction (Sehnert et al., 2002;
Ahmad et al., 2008). Similarly, C-terminal truncations of zebrafish
tnnt2 (exclusion of exon 12; see supplementary material Fig. S1 for
exon numbering) almost completely abolish myocardial contraction
and are associated with a total loss of wild-type tnnt2 transcript
(Huang et al., 2009). We sought to model a dominant human tnnt2
mutation, avoiding the non-physiological elimination of contractile
function and its resultant effects on cardiogenesis.
In conclusion, recapitulation of human hypertrophic
cardiomyopathy gene mutations in the zebrafish facilitates access
to the earliest effects of these genetic perturbations. We were able
to confirm the primary defects in sarcomere assembly and
establish the activation of a subset of hypertrophic pathways as
well as the presence of abnormal Ca2+ handling during initial
cardiogenesis. We also obtained definitive evidence for a
hyperplastic cardiomyocyte response to a genetic hypertrophic
stimulus during development. Although this might simply reflect
the plastic environment of the embryo or a general property of
the zebrafish heart, it will be important to re-evaluate the role of
regional perturbations in cell number in the unique features of
HCM, such as asymmetric septal hypertrophy. In addition,
understanding the comparative biology of hyperplastic and
hypertrophic responses across a range of species may inform
efforts to manipulate terminally differentiated cardiomyocytes or
cardiac progenitor cell populations in human disease. Ultimately,
our work suggests that the pleiotropy of human hypertrophic
cardiomyopathy may be influenced by selection pressures exerted
during development.
METHODS
The investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996).
Morpholino injection
Morpholinos (Gene Tools, LLC, Philomath, OR) were resuspended
in 1 Danieu’s solution and 5 ng injected into fertilized eggs from
TuAB fish at the single-cell stage. The tnnt2 exon 13 splice
(TNNT2sp) MO sequence was: 5-TAGACACAGATG AAC T -
CACAATTTC-3. There is a polymorphism at the morpholino-
binding site in exon 13 that is highlighted in red in supplementary
material Fig. S1. The 5 bp mismatch control morpholino sequence
was (base changes are lower case): 5-TAcACAgAGATcAACTCA -
gAATaTC-3. To determine whether the morpholino altered
splicing of the tnnt2 mRNA, we designed primers that flanked tnnt2
exon 13 and then performed RT-PCR. Primer sequences are
TNNT2ex11F: 5-AGAAGAAGATTCTCGGTGATCG-3 and
TNNT2ex14R: 5-CAACAGTGGTCAGCTCCTCTC-3. We
sequenced the PCR product to confirm that exon 13 was completely
excluded. The TNNT2atg (‘silent heart’) morpholino sequence is
5-CATGTTTGCTCTGATCTGACACGCA-3 (Sehnert et al.,
2002).
Electron microscopy
Embryos were fixed at 96 hpf, 8 dpf and 21 dpf, embedded in Epon
812 (Polysciences) and sectioned. Thin sections were cut on a
Reichert Ultracut E ultramicrotome and collected onto Formar-
coated slot grids. Sections were post-stained with uranyl acetate
and lead citrate, and viewed in a Philips CM10 electron microscope
at 80 keV.
Myocardial function
Embryos were laterally positioned and allowed to acclimate. Video
microscopy was performed with an Axioplan (Zeiss) upright
microscope and 544 frames were digitally captured at identical
levels of magnification (10) and frame rate (250 frames per
second). Sequential still frames were analyzed to identify ESD and
EDD. FS was calculated using the formula (EDD – ESD)/(EDD).
Cardiomyocyte quantification
cmlc2::DsRed-nuc embryos were injected with control or TNNT2sp
MO at the one-cell stage. At 48 or 96 hpf the embryos were
euthanized and fixed in 4% PFA for 12 hours at 4°C. The embryos
were transferred to PBS and stored at 4°C. Whole embryos were
mounted in 1% low-melt agar and were imaged using a Zeiss LSM5
Pascal confocal microscope and 40water-immersion lens. z-stack
images were collected and a three-dimensional image projection
was created using ImageJ (NIH). DsRed-positive nuclei were then
counted using ImageJ software.
Cell size measurement
Control and TNNT2sp morphant embryos were euthanized and
fixed in 4% PFA for 12 hours at 4°C. They were then transferred
to 100% methanol and stored at –20°C. The embryos were then
rehydrated in PBST. After rehydration, the embryos were washed
in a blocking buffer (2 mg/ml BSA, 2% goat serum, 1% DMSO in
PBST) for 2 hours at 25°C. They were then incubated with mouse
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anti-ZN8 (binds to ventricular cardiomyocyte cell surface)
[Developmental Studies Hybridoma Bank (DSHB); 1:50] at 4°C for
12 hours, and then with Alexa Fluor 546 (Invitrogen; 1:1000) for 3
hours at 25°C. Whole embryos were mounted in 1% low-melt agar
and were imaged using a Zeiss LSM5 Pascal confocal microscope
and 40 water-immersion lens. ImageJ analysis software was used
to measure the cell surface area of control and TNNT2sp morphant
cardiomyocytes.
Ca2+ imaging
Hearts were isolated from zebrafish embryos at 72 hpf and placed
in normal Tyrode’s solution (NT), which contained (in mM) Na+
(136), K+ (5.4), Mg2+ (1.0), PO43– (0.3), Ca2+ (1.8), glucose (5.0)
and HEPES (10.0) at pH 7.4. The chamber was mounted on the
stage of an inverted microscope (TE-2000, Nikon). Excitation
light was generated by a 120 W metal halide lamp (X-Cite 120,
Exfo), transmitted through a 525/50 nm excitation filter and
reflected onto the preparation by a 560-nm-cutoff dichroic
mirror. Fluorescence emission was passed through a 635 nm
long-pass emission filter and reflected by a mirror towards the
camera, which was mounted at a side-port. For ratiometric Ca2+
transient recordings, hearts were loaded for 15 minutes with 50
M of the Ca2+-sensitive dye Fura-2, AM (Invitrogen). Hearts
were then incubated in NT solution at room temperature for 30-
45 minutes to allow complete intracellular hydrolysis of the
esterified dye and placed in a perfusion bath (Warner
Instruments) that contained NT solution supplemented with 30
M of the excitation-contraction uncoupler blebbistatin
(Calbiochem) to inhibit motion. A high-speed monochromator
(Optoscan, Cairn Research, UK) was used to rapidly switch the
excitation wavelength between 340 nm and 380 nm with a
bandwidth of 20 nm and at a rate of 500 second–1. Wavelength
switching was synchronized with the camera to ensure that
fluorescence acquisition occurred at well-defined time intervals,
i.e. when the monochromator had reached the two target
wavelengths. Each ratio acquisition required four frames, thus
resulting in a final ratio rate of 125 second–1. The excitation light
was reflected by a 400-nm-cutoff dichroic mirror and
fluorescence emission was collected by the camera through a
510/80 nm emission filter. For the measurement of fluorescence
intensities, a high-speed 8080-pixel CCD camera (CardioCCD-
SMQ, RedShirtImaging, LLC) with 14-bit resolution was used.
Using a 20/0.75 NA objective and a 0.5 C-mount adapter,
the final magnification was 10, resulting in a pixel-to-pixel
distance of 2.2 m.
Fluorescence data signal processing and Ca2+ transient analysis
Acquired fluorescence images were exported as TIFF stacks and
analyzed using Matlab (Mathworks) software. Regions of interest
(ROIs) 1616 pixels in size, covering an area of about 3535 m
of epicardial tissue, were defined within the atrium,
atrioventricular junction, and the inner curvature (IC) and the
outer curvature (OC) of the ventricle. The size of the ROI was
the same for all measurements. Errors resulting from variations
in the positions of these ROIs within each target area (e.g. atrium,
ventricle) of the same heart were less than 10% and smaller than
the naturally occurring variations of Ca2+ concentrations between
different hearts of the same genotype. Individual Ca2+ transients
were extracted from each pixel contained within each ROI to
calculate minimum (diastolic) and maximum (systolic)
fluorescence ratios. Ca2+ transient amplitude was defined as the
difference between the systolic and diastolic ratios, and transient
duration (CTD50) as the time difference between the upstroke
and the decay phases, measured at 50% of the amplitude. Diastolic
ratios, transient amplitudes and transient durations were
calculated and measurements averaged for all pixels within each
ROI.
Gene expression analysis
Control- and TNNT2sp-MO-injected embryos were collected at
96 hpf in groups of 40 embryos, and RNA was extracted using Trizol
(Invitrogen) and further purified with RNeasy columns (Qiagen).
Four biological replicates of control and TNNT2sp embryos were
then analyzed using a two-color zebrafish-specific microarray
(Agilent). Primary microarray data files and matrix files are available
at NIH GEO repository – GSE20179.
All statistical analysis was performed using the R software
package (2.9.2; www.cran.r-project.org). Agilent two-color
microarray data were analyzed using the limma package. Limma
employs a generalized linear model with empirical Bayesian
methods to ‘borrow information’ across genes for more stable
estimates of significance and magnitude of change, especially
when the number of arrays is small. Unadjusted P-values for
association were input into the fdrtool package for empirical tail-
based false discovery rate (FDR) calculation (Strimmer, 2008). An
arbitrary FDR threshold of 0.15 was selected – at this threshold,
we expect that >85% of the ‘significant’ probe sets represent true
positives. We have found that these relaxed thresholds combined
with further pathway analysis methods can be useful for
identifying enriched pathways. The FuncAssociate program was
used for examining GO term enrichment (supplementary material
Table S2).
A previously published hypertrophic cardiomyopathy P-MAGE
data set (all tags significant at P0.05) was downloaded for
comparison of significantly changed orthologs (Kim et al., 2007).
Mouse orthologs for zebrafish genes were identified using
a  combination of the Inparanoid, Zfin and Ensembl
(www.ensembl.org) databases (Ostlund et al., 2010; Sprague et al.,
2008). An additional number of orthologs were identified by
matching symbol names and performing bidirectional BLASTN to
ensure that the corresponding ortholog represented the top BLAST
hit in each case. A total of 122 orthologs were significant at P0.05
(P-MAGE) and the FDR was 0.15 (zebrafish array). We compared
the direction of change for each of these and found 74 that
demonstrated concordant change. Statistical significance was
assessed as follows. Under the null model, we would expect a 50%
probability for the concordance for any given pair of orthologs. The
probability that 74 or more of these 122 orthologs are concordant
is thus given by the cumulative binomial distribution with n122
and P0.5, analogous to the probability of 74 heads in 122 flips of
a fair coin. To identify similarities in patterns of change for different
probe sets, the limma coefficients for the 74 probe sets with
concordant change in the P-MAGE and microarray data sets were
depicted in a heatmap, using the heatmap function in R.
FuncAssociate uses a hypergeometric test and correction for
multiple hypothesis testing to formally evaluate statistical
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significance for pathway enrichment (Berriz et al., 2009).
Upregulated and downregulated genes were analyzed separately
and ranked by magnitude of change. For some genes, multiple probe
sets were available, usually with differing magnitude and
significance of change. We operated under the assumption that
differing effect sizes for multiple probe sets arises from some
combination of chance variation in probe binding efficiencies,
differential regulation of individual isoforms and measurement
error. Because a single probe set had to be selected for subsequent
analyses, for those genes mapping to multiple probe sets, the probe
set with the lowest P-value was selected, thus making the optimistic
assumption that the lowest P-value was capturing the true, maximal
change in response to the perturbation. Although this assumption
might introduce noise in further analyses, it should not introduce
any systematic bias in terms of direction of change.
qPCR was performed using RNA extracted from whole embryos
using Trizol reagent (Invitrogen) and reverse transcribed with the
QuantiTect Reverse Transcription Kit (Qiagen). Gene-specific
primers and SYBR Green reagent (Applied Biosystems) were used
to perform the PCR portion of the experiment. The Ct method
was used to normalize the gene of interest to the endogenous
housekeeping gene Rpl13alpha. Then the experimental sample was
divided by the control sample to determine the level of induction.
qPCR primer sequences: nppa: F 5-GATGTACA AGCG C -
ACACGTT-3, R 5-TCTGATGCCTCTTCTGTTGC-3; ghrh: F
5-AGACTTGGACCAGAAACTGAAAGC-3, R 5-TGTGGGT -
CTCTGTAACTTTGTTCA-3; 13alpha: F 5-TCT GGA GGACT -
GTAAGAGGTATGC-3, R 5-AGACGCACAATC TTGAGAG -
CAG-3.
Statistics
To compare two continuous variables a Student’s t-test was used
for normally distributed data. For data that were not normally
distributed, a Wilcoxon rank-sum test was used. All data are
expressed as mean ± s.e.m., unless otherwise noted.
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